Literature DB >> 10746676

Sarcomatoid carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical analysis of 14 patients.

H Ikegami1, H Iwasaki, Y Ohjimi, T Takeuchi, A Ariyoshi, M Kikuchi.   

Abstract

Sarcomatoid carcinoma of the urinary bladder is a rare entity, in which both the histogenesis and biological behavior remain controversial. We herein describe the clinicopathologic and immunohistochemical profiles of sarcomatoid carcinomas and discuss the significance of cell adhesion molecules in the development of this peculiar neoplasm. The authors examined formalin-fixed and paraffin-embedded tissue samples from 14 patients with sarcomatoid carcinoma of the urinary bladder. An immunohistochemical analysis was performed by using antibodies against epithelial and mesenchymal antigens as well as adhesion molecules. Most patients suffered from an advanced stage of the tumor, extending to the muscular layer (7 cases) or to the perivesical tissues (5 cases). Microscopically, all 14 tumors were composed predominantly of a carcomatoid component and an obviously carcinomatous component. The sarcomatoid component was composed of a mixture of spindle cells, round cells, and pleomorphic giant cells. The carcinomatous components consisted of papillary or nonpapillary high-grade transitional cell carcinoma (TCC). The zones of gradual transition between the carcinomatous and the sarcomatous elements were focally apparent in each tumor. The findings of an immunohistochemical examination indicated that both carcinomatous and sarcomatoid components expressed epithelial antigens (pankeratin or EMA), even though the staining pattern varied from case to case. As for cell adhesion molecules, the carcinomatous components were positive for E-cadherin (8 of 12), CD44s (8 of 12), and CD44v6 (6 of 12). Although the sarcomatoid components were also positive for E-cadherin (5 of 12), CD44s (4 of 12), and CD44v6 (3 of 12), these rates were lower than those in the carcinomatous components. Six patients died of their disease between 5 and 36 months after the diagnosis was made. The recognition of sarcomatoid carcinomas has important therapeutic and prognostic implications. It seems appropriate to treat these neoplasms in the same manner as conventional high-grade TCCs with similar degrees of invasion. We consider that sarcomatoid carcinomas should be regarded as a high-grade carcinoma that shows a prominent pseudosarcomatous dedifferentiation. The sarcomatoid component of sarcomatoid carcinomas may result from either anaplastic changes or dedifferentiation related to the process of losing cell adhesion molecules.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10746676     DOI: 10.1016/s0046-8177(00)80247-6

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  18 in total

1.  Bladder preserving approach for liposarcomatoid variant of transitional urothelial carcinoma.

Authors:  S K Singh; Ankur Mittal; Abhinandan Mukhopadhyay; Nandita Kakkar; Debajyoti Chatterjee
Journal:  Can Urol Assoc J       Date:  2015-12-14       Impact factor: 1.862

Review 2.  Leiomyosarcoma of the urinary bladder presenting as life threatening gross hematuria.

Authors:  Thomas Nelius; J Stevens; C Samathanam; S Filleur
Journal:  Med Oncol       Date:  2009-06-11       Impact factor: 3.064

3.  Urothelial carcinoma of the sarcomatoid variant in a young patient with spina bifida: a case report and review of the literature.

Authors:  Michael Nomikos; Prodromos Philippou; Chrysa Glava; Dimitrios Delakas
Journal:  Cases J       Date:  2009-12-22

Review 4.  Sarcomatoid carcinoma with small cell carcinoma component of the urinary bladder: a case report with review of the literature.

Authors:  Mitsuaki Ishida; Muneo Iwai; Keiko Yoshida; Akiko Kagotani; Hidetoshi Okabe
Journal:  Int J Clin Exp Pathol       Date:  2013-07-15

5.  Primary bone carcinosarcoma of the fibula with chondrosarcoma and squamous cell carcinoma components.

Authors:  Mitsuaki Ishida; Narihito Kodama; Yoshinori Takemura; Muneo Iwai; Keiko Yoshida; Akiko Kagotani; Yoshitaka Matsusue; Hidetoshi Okabe
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15

6.  Sarcomatoid carcinoma of the urinary bladder: a case report with immunohistochemical and molecular genetic analysis.

Authors:  Tadashi Terada
Journal:  Med Oncol       Date:  2009-06-12       Impact factor: 3.064

7.  Extensive rhabdomyosarcomatous differentiation in recurrent low-grade urothelial carcinoma of the bladder after transurethral resection: a case report.

Authors:  Maiko Kamei; Tsutomu Shinohara; Kotaro Kasahara; Takahira Kuno; Keishi Naruse; Hironobu Watanabe
Journal:  J Med Case Rep       Date:  2015-09-10

8.  Urinary bladder carcinoma with triplicate differentiations into giant cell sarcomatoid carcinoma, squamous cell carcinoma, and papillary urothelial transitional cell carcinoma: a case report.

Authors:  Tadashi Terada
Journal:  Cases J       Date:  2009-11-30

9.  Pulmonary sarcomatoid carcinoma: a case report.

Authors:  Xiao-Yong Shen; Zhi-Feng Lin; Qiang Lin; Zhen Ruan; Hai-Long Huang; Chao-Qiang Ju; Jin Wang
Journal:  Contemp Oncol (Pozn)       Date:  2013-04-29

Review 10.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.